PHARMACEUTICAL COMPOSITION

1 . An oral pharmaceutical composition, comprising

(i) an active ingredient selected from a compound of formula (II),

or salts or solvates thereof, wherein said active ingredient is present at a concentration of 30-60 percent by weight;

(ii) at least one binder wherein said binder is present at a concentration of 4 to 9 percent by weight;

(iii) at least one disintegrant wherein the disintegrant is present in a range of 2 to 8 percent by weight;

(iv) at least one lubricant wherein the at least one lubricant, is present in a range of 0.6 to 1.3 percent by weight; and

(v) at least one diluent wherein the at least one diluent, is present in a range of 35 to 50 percent by weight.

2 . The oral pharmaceutical composition of claim 1 wherein at least one diluent is microcrystalline cellulose.

3 . The oral pharmaceutical composition of claim 1 wherein the at least one diluent, is present in a range of 40 to 46 percent by weight.

4 . The oral pharmaceutical composition of claim 1 wherein at least one lubricant is magnesium stearate.

5 . The oral pharmaceutical composition of claim 1 wherein the at least one lubricant, is present in a range of 0.8 to 1 percent by weight.

6 . The oral pharmaceutical composition of claim 1 wherein at least one disintegrant is sodium starch glycolate.

7 . The oral pharmaceutical composition of claim 1 wherein the disintegrant is present in a range of 3.5 to 5 percent by weight.

8 . The oral pharmaceutical composition of claim 1 wherein said active ingredient is the ditosylate salt of the compound of formula (II).

9 . The oral pharmaceutical composition of claim 8 wherein said active ingredient is N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate.

10 . The oral pharmaceutical composition of claim 1 wherein said active ingredient is present in a range of 45-51 percent by weight.

11 . The oral pharmaceutical composition of claim 1 wherein said active ingredient, binder, disintegrant, lubricant, and diluent are comprised within a core tablet composition.

12 . The oral pharmaceutical composition of claim 11 wherein said oral composition additionally comprises a film coat.

13 . The oral pharmaceutical composition of claim 12 wherein said film coat is present in the range of 2.5 to 3.5 percent by weight of the core tablet composition.

14 . The oral pharmaceutical composition of claim 13 wherein said film coat is present in the range of 2.8 to 3.2 percent by weight of the core tablet composition.

15 . The oral pharmaceutical composition of claim 9 , wherein the at least one binder is povidone.

16 . The oral pharmaceutical composition of claim 1 wherein said binder is present at a concentration of 5.5 to 7.5 percent by weight.

17 . An oral pharmaceutical composition comprising:

(i) N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate;

(ii) povidone;

(iii) sodium starch glycolate;

(iv) microcrystalline cellulose; and

(v) magnesium stearate.

18 . The oral pharmaceutical composition of claim 17 wherein:

(i) said N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate is present in a range of 30 to 47 percent by weight;

(ii) said povidone is present in a range of 4 to 9 percent by weight;

(iii) said sodium starch glycolate is present in a range of 2 to 8 percent by weight;

(iv) said microcrystalline cellulose is present in a range of 35 to 50 percent by weight; and

(v) said magnesium stearate is present in a range of 0.6 to 1.3 percent by weight.

19 . The oral pharmaceutical composition of claim 18 herein:

(i) said N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate is present in a range of 30 to 60 percent by weight;

(ii) said povidone is present in a range of 4 to 9 percent by weight;

(iii) said sodium starch glycolate is present in a range of 2 to 8 percent by weight;

(iv) said microcrystalline cellulose is present in a range of 35 to 50 percent by weight; and

(v) said magnesium stearate is present in a range of 0.6 to 1.3 percent by weight.

20 . The oral pharmaceutical composition of claim 19 wherein:

(i) said N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate is present in a range of 42 to 48 percent by weight;

(ii) said povidone is present in a range of 5.5 to 7.5 percent by weight;

(iii) said sodium starch glycolate is present in a range of 3.5 to 5.5 percent by weight;

(iv) said microcrystalline cellulose is present in a range of 40 to 46 percent by weight; and

(v) said magnesium stearate, is present in a range of 0.8 to 1.2 percent by weight.

21 . The oral pharmaceutical composition of claim 20 wherein:

(i) said N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine ditosylate monohydrate is present in a range of 45 to 51 percent by weight;

(ii) said povidone is present in a range of 5.5 to 7.5 percent by weight;

(iii) said sodium starch glycolate is present in a range of 3.5 to 5.5 percent by weight;

(iv) said microcrystalline cellulose is present in a range of 40 to 46 percent by weight; and

(v) said magnesium stearate is present in a range of 0.8 to 1.2 percent by weight.